BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial
Data and Safety Monitoring Board to initiate second dose in Ph2a of BGBC016 trial
The recommendation of the DSMB allows
The Phase 2a is assessing the safety and efficacy of two different doses of bemcentinib in the same treatment combination. As previously communicated, the company expects to present an interim analysis in the second half of this year.
Contacts
ir@bergenbio.com
rune.skeie@bergenbio.com
Investor Relations / Media Relations
jl@lillebyfrisch.no
About STK11m NSCLC
Patients with STK11m NSCLC have a significantly poorer response to current therapies, including immune checkpoint inhibitors, when compared with patients with wild-type (non-mutated) STK11. AXL plays a significant role in the survival and spread of cancer and STK11m NSCLC patients have a high expression of AXL suggesting that AXL is an important target to prevent disease progression and resistance to existing therapies. Bemcentinib's selective inhibition of AXL has been shown to improve the response to immune checkpoint inhibition in STK11m patient-derived preclinical models and in early clinical studies. There are currently no targeted therapies available for the STK11m NSCLC patient population, which represents up to 20% of 1L NSCLC patients.
About
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.co.uk/news-releases/bergenbio-announces-selection-of-2nd-dose-in-phase-2a-first-line-stk11m-non-small-lung-cancer-trial-302208346.html